BG103000A - Compositions for single daily dosage in the treatment of cyclooxygenase-2-dependent diseases - Google Patents

Compositions for single daily dosage in the treatment of cyclooxygenase-2-dependent diseases

Info

Publication number
BG103000A
BG103000A BG103000A BG10300098A BG103000A BG 103000 A BG103000 A BG 103000A BG 103000 A BG103000 A BG 103000A BG 10300098 A BG10300098 A BG 10300098A BG 103000 A BG103000 A BG 103000A
Authority
BG
Bulgaria
Prior art keywords
cyclooxygenase
treatment
single daily
above compound
compositions
Prior art date
Application number
BG103000A
Other languages
Bulgarian (bg)
English (en)
Inventor
Bruno Hancock
Conrad Winters
Barry Gertz
Elliot Ehrich
Original Assignee
Merck & Co. Inc.
Merck Frosst Canada & Co./Merck Frosst Canada & Cie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26309472&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG103000(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9612063.9A external-priority patent/GB9612063D0/en
Application filed by Merck & Co. Inc., Merck Frosst Canada & Co./Merck Frosst Canada & Cie filed Critical Merck & Co. Inc.
Publication of BG103000A publication Critical patent/BG103000A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
BG103000A 1996-05-17 1998-12-08 Compositions for single daily dosage in the treatment of cyclooxygenase-2-dependent diseases BG103000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1787896P 1996-05-17 1996-05-17
GBGB9612063.9A GB9612063D0 (en) 1996-06-10 1996-06-10 Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
PCT/US1997/008041 WO1997044028A1 (fr) 1996-05-17 1997-05-13 Compositions pour traitement journalier monodose de maladies a mediateur cyclooxygenase-2

Publications (1)

Publication Number Publication Date
BG103000A true BG103000A (en) 1999-09-30

Family

ID=26309472

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103000A BG103000A (en) 1996-05-17 1998-12-08 Compositions for single daily dosage in the treatment of cyclooxygenase-2-dependent diseases

Country Status (28)

Country Link
US (1) US6063811A (fr)
EP (1) EP0910368A1 (fr)
JP (1) JPH11512754A (fr)
KR (1) KR100373622B1 (fr)
CN (1) CN1140267C (fr)
AR (1) AR012014A1 (fr)
AU (1) AU3004997A (fr)
BG (1) BG103000A (fr)
BR (1) BR9709097A (fr)
CA (1) CA2254061C (fr)
CO (1) CO5050370A1 (fr)
CZ (1) CZ291463B6 (fr)
DZ (1) DZ2200A1 (fr)
EA (1) EA001596B1 (fr)
EE (1) EE03746B1 (fr)
HR (1) HRP970262A2 (fr)
HU (1) HUP9902889A3 (fr)
ID (1) ID16921A (fr)
IL (1) IL126899A (fr)
IS (1) IS4891A (fr)
MY (1) MY116201A (fr)
NO (1) NO985342D0 (fr)
NZ (1) NZ332670A (fr)
PE (1) PE66998A1 (fr)
PL (1) PL188649B1 (fr)
SK (1) SK284330B6 (fr)
TR (1) TR199802345T2 (fr)
WO (1) WO1997044028A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
WO1999045913A1 (fr) * 1998-03-13 1999-09-16 Merck & Co., Inc. Therapie associee destinee au syndrome ischemique coronarien aigu ainsi qu'a des troubles connexes
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
CO5190664A1 (es) 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
GB9920558D0 (en) * 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
CN1434713A (zh) * 1999-12-22 2003-08-06 法马西亚公司 环加氧酶－2抑制剂的缓释制剂
ATE511844T1 (de) 2000-06-13 2011-06-15 Wyeth Llc Analgetische und entzündungshemmende zusammensetzungen enthaltend celecoxib und ibuprofen
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
DE60120710T2 (de) * 2000-08-18 2007-06-14 Pharmacia Corp. Schnell zerfallende orale arzneizubereitung enthaltend valdecoxib
US8680081B2 (en) * 2000-08-29 2014-03-25 Peter Van Patten Prophylactic treatment of migraine
AR030630A1 (es) * 2000-09-11 2003-08-27 Novartis Ag Composiciones farmaceuticas
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
CA2445502A1 (fr) * 2001-05-04 2002-11-14 Merck & Co., Inc. Procede et compositions pour le traitement des migraines
PE20030323A1 (es) * 2001-08-31 2003-05-12 Novartis Ag Composicion farmaceutica
CN1633281A (zh) * 2001-09-26 2005-06-29 法马西亚公司 口内崩解的伐地考昔组合物
EP1450769A1 (fr) * 2001-10-10 2004-09-01 Pharmacia Corporation Compositions de valdecoxib a desintegration intra-orale preparees a l'aide d'un procede de sechage par pulverisation
CA2476744A1 (fr) * 2002-03-07 2003-09-12 Novartis Ag Compositions pharmaceutiques solides comprenant du lumiracoxib
ES2214129B1 (es) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 3-fenilfuran-2-onas.
ES2213485B1 (es) 2003-02-13 2005-12-16 Almirall Prodesfarma, S.A. Derivados de la 2-fenilpiran-4-ona.
ATE342722T1 (de) 2003-05-07 2006-11-15 Osteologix As Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
TR200301552A1 (tr) * 2003-09-18 2005-10-21 Nobel İlaç Sanayi̇ Ve Ti̇caret A. Ş. Rofekoksib' in yeni oral farmakolojik formülasyonları.
EP2114461A2 (fr) * 2007-01-19 2009-11-11 Mallinckrodt Inc. Ligands de liaison à la cycloxygénase-2 diagnostiques et thérapeutiques
MX2021005967A (es) 2018-11-21 2021-10-13 Tremeau Pharmaceuticals Inc Formas purificadas de rofecoxib, métodos de fabricación y uso.
WO2020210373A1 (fr) * 2019-04-09 2020-10-15 Tremeau Pharmaceuticals, Inc. Traitement des fièvres hémorragiques virales avec de l'étoricoxib
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
CN1143365A (zh) * 1994-01-10 1997-02-19 麦克弗罗斯特(加拿大)有限公司 作为cox-2抑制剂的苯基杂环类化合物

Also Published As

Publication number Publication date
KR100373622B1 (ko) 2003-07-12
HUP9902889A3 (en) 2002-04-29
PL329940A1 (en) 1999-04-26
AU3004997A (en) 1997-12-09
CA2254061A1 (fr) 1997-11-27
NZ332670A (en) 2000-07-28
CZ373898A3 (cs) 1999-06-16
DZ2200A1 (fr) 2004-06-20
SK156798A3 (en) 2000-01-18
CA2254061C (fr) 2003-12-02
NO985342L (no) 1998-11-16
PL188649B1 (pl) 2005-03-31
AR012014A1 (es) 2000-09-27
SK284330B6 (sk) 2005-01-03
CO5050370A1 (es) 2001-06-27
TR199802345T2 (xx) 1999-03-22
EE03746B1 (et) 2002-06-17
US6063811A (en) 2000-05-16
CN1225010A (zh) 1999-08-04
IL126899A (en) 2004-03-28
EP0910368A1 (fr) 1999-04-28
JPH11512754A (ja) 1999-11-02
ID16921A (id) 1997-11-20
EE9800393A (et) 1999-06-15
HUP9902889A2 (hu) 2002-01-28
HRP970262A2 (en) 1998-06-30
PE66998A1 (es) 1998-10-24
IL126899A0 (en) 1999-09-22
IS4891A (is) 1998-11-10
CN1140267C (zh) 2004-03-03
EA199801017A1 (ru) 1999-04-29
WO1997044028A1 (fr) 1997-11-27
KR20000011082A (ko) 2000-02-25
BR9709097A (pt) 1999-08-03
HK1021623A1 (en) 2000-06-23
CZ291463B6 (cs) 2003-03-12
NO985342D0 (no) 1998-11-16
MY116201A (en) 2003-11-28
EA001596B1 (ru) 2001-06-25

Similar Documents

Publication Publication Date Title
BG103000A (en) Compositions for single daily dosage in the treatment of cyclooxygenase-2-dependent diseases
MY141773A (en) (methylsulfonyl)phenyl-2-(5h)-furanones as cox-2 inhibitors
UA66750C2 (en) Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors
AU7449598A (en) Medicinal composition for prevention or treatment of hepatopathy
NZ514574A (en) Novel method of treatment
BG103795A (en) Pharmaceutical compositions with appetite suppressing activity
EP0209689A3 (en) Use of tetrahydrobiopterins in the treatment of infantile autism
YU49026B (sh) UPOTREBA 17 Гџ -(N-TERC-BUTILKARBAMOIL)-4-AZA-5-ALFA-ANDROST-1-3-ON ZA PROIZVODNJU LEKA ZA TRETIRANJE ANDROGENE ALOPECIJE
BG102526A (bg) Твърди дозирани форми, съдържащи флурбипрофен
AU1537095A (en) Therapeutic agents containing thyroid hormones
IL118637A0 (en) Oral pharmaceutical compositions of S(+)-ibuprofen
MX9709238A (es) Formulaciones farmaceuticas y de dieta para la profilaxis y tratamiento de trastornos gastrointestinales.
NZ318282A (en) Pharmaceutical formulation containing amoxycillin and clavulanate in a weight ratio of 12:1 and 20:1
EP0119161A3 (en) Benzazoquinone and benzazoninone derivatives, process for their preparation, their pharmaceutical preparations as well as their therapeutic use
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
MX9706647A (es) Composiciones farmaceuticas que comprenden inhibidores de oxidasa b de monoamina.
WO1987007835A1 (fr) Medicament pour le traitement et la prophylaxie de maladies du rein et du foie
AU4011300A (en) Compositions and methods for the treatment of immune related diseases
NZ326345A (en) Composition containing diosgenin
DE69816047D1 (en) (methylsulfonyl)phenyl-2-(5h)-furanone mit sauerstoff-bindung als cox-2-hemmer
LT96093A (en) The active ingredient of pharmaceutical composition for treating aphtae and stomatitis
AU4434389A (en) Aqueous oral pharmaceutical preparation of diclofenac
AU580079B2 (en) Acetylenic phenoxypropanol derivatives and pharmaceutical compositions for the treatment of hypertension
GR1002576B (el) Φαρμακευτικες συνθεσεις και μια μεθοδος παρασκευης τους.
CA2077693A1 (fr) Utilisation du ketorolac pour le traitement de la parodontopathie